ClinicalTrials.gg
Not yet recruitingNCT07294313Updated Mar 20, 2026

Harnessing Artificial Intelligence for Diagnosing Androgenetic Alopecia: A Training and Validation Study

An observational study in Androgenetic Alopecia, sponsored by Cairo University. Not yet recruiting at 1 site in Egypt. Open to participants aged 12 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by Cairo University · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
400
Ages
12 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.

Started
2026
with 4 others
Observational
4 of 25
1 open now
Registered
18th of 25
by date
Lead sponsor
6 of 25
Cairo University

Among the 25 studies in Alopecia with a site in Egypt, this one is one of 5 that started in 2026, is one of 4 observational ones, and was the 18th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 12 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Alopecia with a site in Egypt, or all of them as a file.
02

Study summary

The aim of this study is to develop and validate deep learning models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image by handheld dermoscopy and administrative data (age and sex).

Read the detailed description

The investigators intend to develop and validate artificial intelligence (AI) and machine learning (ML) models in diagnosis of male and female pattern hair loss, and assessment of its severity based on clinical and trichoscopic image using widely available and accessible handheld dermoscopes.

Conventional androgenetic alopecia (AGA) diagnosis and severity assessment are tedious and time-consuming tasks that are prone to human errors. These challenges can be tackled using artificial intelligence (AI), namely leveraging applications of machine learning and artificial neural networks for enhancing the diagnostic accuracy of scalp disease classification systems via dermoscopic image analysis. Computer aided assessment of hair microphotographs was attempted for decades, yet it faced many technical hurdles before the onset of deep learning and neural networks; and currently available software generate inaccurate results compared with visual counting. More accurate methods of analysis are needed for trichoscopic imaging, utilising deep learning image recognition models trained with a large image dataset. A number of deep learning models have been developed in recent years using videodermoscopy that achieved reliable hair density, thickness and severity classification, yet remain limited by small non-inclusive training datasets, need for hair shaving and lack of detailed reporting. Moreover, to our knowledge all previous models depend on image acquisition from expensive standalone videodermoscopy devices that lack widespread availability, rather than handheld dermoscopes that are commonly available.

The study will enroll 400 participants (200 healthy controls and 200 AGA patients). Controls undergo history and trichoscopic exams to exclude hair disorders. Trichoscopic examination will be conducted using a handheld dermoscope (CuTechs DS175) with a specialized field spacer. Patients will be assessed for disease severity using gender-specific scales. Both groups will have standardized digital and trichoscopic images taken for analysis. Images will be used to manually count and classify hairs, assess follicle units, and identify dermoscopic signs. A structured database will store all data and link clinical and image data to support objective diagnosis. AI models, particularly CNNs using transfer learning, will be trained on preprocessed images for classification and severity scoring. Model performance will be evaluated using metrics like accuracy, precision, recall, F1-score, and AUC-ROC compared with metrics reported by expert trichologists to validate accuracy and reliability

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

Keywords

  • Androgenetic Alopecia
  • deep learning
  • Artificial Intelligence
  • Convoluted neural network
  • trichoscopy
  • female pattern hair loss
  • male pattern hair loss
  • handheld dermoscope
  • hair count
04

Who can participate

Ages eligible
12 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders and apparently healthy controls.

Eligibility criteria

for the patient group:

Inclusion criteria:

  • Patients with male or female pattern hair loss diagnosed clinically or suspected clinically and confirmed trichoscopically
  • Age of disease onset 12-50 years old
  • Both genders
  • Any grade of androgenetic alopecia
  • Any duration of androgenetic alopecia
  • Any skin type

Exclusion criteria by clinical and trichoscopic examination:

  • Patients with patchy hair loss or Telogen effluvium only.
  • Patients with cicatricial alopecia or diffuse alopecia areata
  • Patients with inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution)
  • Lack of patient cooperation.

for the control group: apparently healthy participants not suffering from the following: AGA, patchy hair loss, cicatricial alopecia, diffuse alopecia areata, inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution).

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No

Groups and cohorts

  • androgenetic alopecia

    Patients diagnosed clinically and trichoscopically with androgenetic alopecia of both genders. The diagnosis of AGA requires fulfillment of the primary criterion, plus one or more of the secondary criteria, and absence of exclusion criteria: * Primary criterion Hair shaft thickness heterogeneity on the frontal and/or vertex scalp, defined as proportion of hairs \< 0.06 mm (including intermediate, thin, and vellus hairs) ≥20%. * Secondary criteria 1. Proportion of single hair follicle unit on the frontal and/or vertex scalp ≥30%. 2. Proportion of vellus hairs on the frontal and/or vertex scalp \>10%. 3. There are at least two other dermoscopic signs: brown peripilar sign, yellow dots,white dots, scalp honeycomb pigmentation * Exclusion criteria Black dots, broken hairs, exclamation mark hairs

  • normal controls

    apparently normal participants not suffering from the following : 1. androgenetic alopecia 2. patchy hair loss. 3. cicatricial alopecia or diffuse alopecia areata 4. inflammatory scalp disorders (psoriasis, seborrheic dermatitis, lichen planopilaris and frontal fibrosing alopecia in a pattern distribution)

06

What researchers measure

Primary outcomes

  1. assessment of diagnostic capability of AI in AGA

    Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in differentiating AGA affected from non-AGA affected subjects using their macroscopic and trichoscopic images.

    Time frame: 1 year

Secondary outcomes

  1. assessment of severity of androgenetic alopecia using AI

    Assess accuracy, sensitivity, specificity and positive predictive value of the trained AI models in assessment of severity of androgenetic alopecia as regards: 1. Clinical classification (Sinclair scale for female pattern baldness and the Hamilton-Norwood scale for male pattern baldness) 2. Trichoscopic parameters: mean hair thickness (in micrometer, using planimetric analysis), hair density (frequency per cm2), proportion of terminal hairs, proportion of vellus hairs, number of hairs per follicular unit, presence of brown peripilar sign, yellow dots, and scalp honeycomb pigmentation.

    Time frame: 1 year

  2. facilitation of AI assessment using macroscopic imagies

    To compare the model's diagnostic accuracy using the macroscopic versus trichoscopic images alone

    Time frame: 1 year

07

Study locations

1 site
08

References and documents

Publications

  • Sacha JP, Caterino TL, Fisher BK, Carr GJ, Youngquist RS, D'Alessandro BM, Melione A, Canfield D, Bergfeld WF, Piliang MP, Kainkaryam R, Davis MG. Development and qualification of a machine learning algorithm for automated hair counting. Int J Cosmet Sci. 2021 Nov;43 Suppl 1:S34-S41. doi: 10.1111/ics.12735. PubMed 34426987 ↗
  • Wang Y, Ding W, Yao M, Li Y, Wang M, Wang L, Li Z, Sun S, Yang M, Zhu Y, Zhou N. Diagnostic and grading criteria for androgenetic alopecia using dermoscopy. Skin Res Technol. 2024 Apr;30(4):e13649. doi: 10.1111/srt.13649. PubMed 38533753 ↗
  • Kuczara A, Waskiel-Burnat A, Rakowska A, Olszewska M, Rudnicka L. Trichoscopy of Androgenetic Alopecia: A Systematic Review. J Clin Med. 2024 Mar 28;13(7):1962. doi: 10.3390/jcm13071962. PubMed 38610726 ↗
  • Young AT, Xiong M, Pfau J, Keiser MJ, Wei ML. Artificial Intelligence in Dermatology: A Primer. J Invest Dermatol. 2020 Aug;140(8):1504-1512. doi: 10.1016/j.jid.2020.02.026. Epub 2020 Mar 27. PubMed 32229141 ↗
  • Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11. PubMed 37166619 ↗
  • Bokhari L, Cottle P, Grimalt R, Kasprzak M, Sicinska J, Sinclair R, Tosti A. Efficiency of Hair Detection in Hair-to-Hair Matched Trichoscopy. Skin Appendage Disord. 2022 Sep;8(5):382-388. doi: 10.1159/000524345. Epub 2022 May 12. PubMed 36161091 ↗

Individual participant data

Plan to share: Yes — relevant praticipant data shall be provided to researchers who request them on reasonable basis

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: from 2027 indefintely

Access criteria: access will be provided to deidentified data including all study parameters

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Sep 2026, 5 months later.

Of 18 observational studies under Alopecia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 38. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2025
First posted
Dec 19, 2025
StartEst.
Apr 25, 2026
Primary completionEst.
Sep 25, 2026
CompletionEst.
Nov 25, 2026
Last update
Mar 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07294313
Lead sponsor
Cairo University
Responsible party
Noura Adel Ahmed Abdelghany Nour (Assistant Lecturer, Cairo University) — Principal investigator
First posted
Dec 19, 2025
Start date
Apr 25, 2026 (estimated)
Primary completion
Sep 25, 2026 (estimated)
Completion
Nov 25, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Noura Nour, MSc, MBBCh
Contact
nouraadel41929@postgrad.kasralainy.edu.eg
00201271451744
Ahmed Mourad, MD
Contact
ahmedmourad@kasralainy.edu.eg
00201021534245

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion